• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

    1/2/25 7:42:04 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Reprogrammed Interchange LLC

    (Last) (First) (Middle)
    101 MISSION STREET, SUITE 1000

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vor Biopharma Inc. [ VOR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/30/2024 P 38,974,101 A (1) 38,974,101(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrant (Right to Buy) $0.838 12/30/2024 P 48,717,626 (3) 12/30/2031 Common Stock 48,717,626 (1) 48,717,626(2) D
    1. Name and Address of Reporting Person*
    Reprogrammed Interchange LLC

    (Last) (First) (Middle)
    101 MISSION STREET, SUITE 1000

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Hoffman Reid

    (Last) (First) (Middle)
    101 MISSION STREET, SUITE 1000

    (Street)
    SAN FRANCISCO CA 94105

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Each share of Common Stock was purchased together with an accompanying Warrant to purchase 1.25 shares of Common Stock. The purchase price of the securities was $0.99425 per share and accompanying Warrant.
    2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
    3. The Warrants are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
    /s/ Frank Huang, Manager of Reprogrammed Interchange LLC 01/02/2025
    /s/ Reid Hoffman 01/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    10/19/2021$40.00Market Outperform
    JMP Securities
    More analyst ratings

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      1/2/25 7:42:04 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Announces Annual Results for Year Ended December 31, 2024

      Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

      4/30/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

      VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.  "We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our cl

      3/20/25 4:05:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Vor Biopharma with a new price target

      Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

      7/26/22 8:25:46 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Vor Biopharma with a new price target

      Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

      4/27/22 6:14:19 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Vor Biopharma with a new price target

      HC Wainwright & Co. initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $26.00

      12/17/21 6:23:13 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ra Capital Management, L.P.

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/23/25 5:47:06 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Resnick Joshua

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/23/25 5:45:40 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Lundberg Sven Ante

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/23/25 5:45:14 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care